Categories: News

Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6, 2023 at 9:30 a.m. Eastern Time in a virtual format.

The Company also announced that its Chairman, President and CEO, Paula Brown Stafford, will provide a corporate update on the Company after the conclusion of the ASM, including the Company’s current focus, positioning and short and long-term plans, and will host a question-and-answer period.

Guests may listen to the 2023 ASM and the business update by visiting and completing the guest login section of the web portal at www.virtualshareholdermeeting.com/NOVN2023. An archived replay of the webcast will be posted for a limited time following the meeting at that same address. If you are not a stockholder of record, you may still access and listen to the meeting, however, guests will be unable to submit questions during the webcast.

Online check-in will begin 15 minutes prior, at 9:15 a.m. ET. The ASM will begin promptly at 9:30 a.m. ET on June 6, 2023.

About Novan

Novan, Inc. is a medical dermatology company focused on developing and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs. The U.S. Food and Drug Administration (“FDA”) accepted for filing Novan’s New Drug Application (“NDA”) seeking approval for berdazimer gel, 10.3% (SB206) for the treatment of molluscum contagiosum. The Company also has a pipeline of potential product candidates using its proprietary nitric oxide-based technology platform, NITRICIL™, to generate new treatments for multiple indications.

INVESTOR AND MEDIA CONTACT:

Jenene Thomas
JTC Team, LLC
833-475-8247
NOVN@jtcir.com

Staff

Recent Posts

Personalized Aroma Recommendation Experience Using SOLO Wellbeing’s Facial Analysis AI Introduced at the “Wellness Lounge” Operated by NTT East, NTT Data, and Storyline

TEL AVIV, Israel, April 24, 2025 /PRNewswire/ -- SOLO Wellbeing Ltd. (Headquarter: Israel, CEO: Roy Tal,…

12 minutes ago

Novo Holdings and EIFO invest €48 million in HealthCap IX to strengthen the Nordic life sciences ecosystem

COPENHAGEN, Denmark, April 24, 2025 /PRNewswire/ -- Novo Holdings and the Export and Investment Fund…

12 minutes ago

ACTO and ScienceMedia Partner to Enhance Clinical Competency and Confidence for Life Sciences Field Teams

AI-powered, on-demand access to clinical content enhances HCP interactions and drives measurable commercial impact for…

12 minutes ago

Former Nike VP & GM Bert Hoyt Joins dBio to Drive Next-Gen Sports & Health Tech as Board Advisor

LUXEMBOURG, April 23, 2025 /PRNewswire/ -- Decentralized Biotechnology Intelligence Holding Group Inc. (dBio), a leading…

6 hours ago

Labroots Open-Access Scientific Virtual Event Lineup: Spring 2025

YORBA LINDA, Calif., April 23, 2025 /PRNewswire/ -- Labroots, the leading scientific social networking website…

6 hours ago

Aleutian Capital Group Advises 1984 System, Inc. dba American Data in Its Sale to Valsoft Corporation

NEW YORK--(BUSINESS WIRE)--Aleutian Capital Group (“Aleutian”) is pleased to announce Valsoft Corporation (“Valsoft”) successful acquisition…

9 hours ago